Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Mylan Labs -- Ignore unavailable to you. Want to Upgrade?

To: Druggist who wrote (263)	3/20/1998 10:55:00 AM
From: David Lawrence	Respond to of 384

NEW YORK, March 20 (Reuters) - Lehman Brothers said analyst Richard Silver upgraded generic drug maker Mylan Laboratories Inc. to outperform from neutral on a trading basis. -- said in report that during the last two months, Mylan has "substantially increased prices on selected older generic products." -- said Wall Street has "yet to fully appreciate the sizable financial impact" of the move. -- raised fiscal 1999 earnings per share estimate to $1.06 from $0.92. -- stock was up 11/16 to 23.